Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca2+ signaling and dysregulated cell metabolism

Velebit, Jelena; Horvat, Anemari; Smolič, Tina; Prpar Mihevc, Sonja; Rogelj, Boris; Zorec, Robert; Vardjan, Nina

doi:10.1038/s41598-020-62864-5

Download PDF

Article
Open access
Published: 07 April 2020

Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca²⁺ signaling and dysregulated cell metabolism

Scientific Reports volume 10, Article number: 6003 (2020) Cite this article

6105 Accesses
48 Citations
15 Altmetric
Metrics details

Subjects

Abstract

Most cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have cytoplasmic inclusions of TAR DNA-binding protein 43 (TDP-43) in neurons and non-neuronal cells, including astrocytes, which metabolically support neurons with nutrients. Neuronal metabolism largely depends on the activation of the noradrenergic system releasing noradrenaline. Activation of astroglial adrenergic receptors with noradrenaline triggers cAMP and Ca²⁺ signaling and augments aerobic glycolysis with production of lactate, an important neuronal energy fuel. Astrocytes with cytoplasmic TDP-43 inclusions can cause motor neuron death, however, whether astroglial metabolism and metabolic support of neurons is altered in astrocytes with TDP-43 inclusions, is unclear. We measured lipid droplet and glucose metabolisms in astrocytes expressing the inclusion-forming C-terminal fragment of TDP-43 or the wild-type TDP-43 using fluorescent dyes or genetically encoded nanosensors. Astrocytes with TDP-43 inclusions exhibited a 3-fold increase in the accumulation of lipid droplets versus astrocytes expressing wild-type TDP-43, indicating altered lipid droplet metabolism. In these cells the noradrenaline-triggered increases in intracellular cAMP and Ca²⁺ levels were reduced by 35% and 31%, respectively, likely due to the downregulation of β₂-adrenergic receptors. Although noradrenaline triggered a similar increase in intracellular lactate levels in astrocytes with and without TDP-43 inclusions, the probability of activating aerobic glycolysis was facilitated by 1.6-fold in astrocytes with TDP-43 inclusions and lactate MCT1 transporters were downregulated. Thus, while in astrocytes with TDP-43 inclusions noradrenergic signaling is reduced, aerobic glycolysis and lipid droplet accumulation are facilitated, suggesting dysregulated astroglial metabolism and metabolic support of neurons in TDP-43-associated ALS and FTD.

APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia

Article Open access 13 March 2024

Identification of senescent, TREM2-expressing microglia in aging and Alzheimer’s disease model mouse brain

Article 18 April 2024

Messenger RNA transport on lysosomal vesicles maintains axonal mitochondrial homeostasis and prevents axonal degeneration

Article Open access 10 April 2024

Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the loss of both upper and lower motor neurons in the brain and spinal cord, and by the progressive paralysis of voluntary muscles and death^1,2. The pathologic hallmark of ALS are cytoplasmic inclusions in motor neurons. In most cases (~95%) of sporadic and familial ALS, TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, has been identified as the key component of these inclusions^{1,2,3,4,5,6,7,8,9}. Moreover, TDP-43 has also been identified as the major protein in inclusions in frontotemporal dementia with ubiquitin-positive inclusions (FTD-U)^2,6.

TDP-43 is a highly conserved protein (414 amino acids), ubiquitously expressed in all tissues and under physiological conditions, primarily localized to the nucleus; however, low levels are also present in the cytoplasm^{2,3,8,10,11,12,13}. TDP-43, an RNA-binding protein, is implicated in multiple aspects of RNA processing, including regulation of transcription, splicing, transport, and stabilization of mRNAs. It also regulates microRNA biogenesis and interacts with DNA. Therefore, its perturbance may lead to significant changes in the transcriptome and proteome^14,15,16,17. It consists of an N-terminal domain, two RNA recognition motifs and a C-terminal prion-like glycine-rich domain that mediates protein-protein interactions with other heterogeneous ribonucleoprotein (hnRNP) family members^2,3,11.

In most pathologic cases, TDP-43 is hyperphosphorylated and ubiquitinated¹⁸. Although ubiquitination targets TDP-43 aggregates for degradation, TDP-43 begins to accumulate in the cytoplasm, suggesting that additional perturbance in either the ubiquitin-proteasome system or the autophagy pathway can facilitate the accumulation of TDP-43 in ALS and FTD-U¹⁹. 25-kDa C-terminal fragments of TDP-43 (TDP-43^208–414) are commonly detected in ALS and FTD-U pathologic specimens, especially in the cerebral cortex, and generation of these fragments is sufficient to initiate a number of events that mirror TDP-43 proteinopathies^2,3,20.

TDP-43-containing cytoplasmic inclusions are not restricted to motor neurons but are also found in non-neuronal cells, in particular in astrocytes²¹. Astrocytes with TDP-43 inclusions are sufficient to cause motor neuron death in animal models^22,23 and exhibit autocytotoxicity⁷. Thus, astrocytes were recently proposed to play an active role in controlling ALS disease progression and may even be the primary driver of TDP-43 proteinopathies^2,7.

Astrocytes are an abundant and heterogeneous subtype of neuroglia in the central nervous system (CNS)²⁴, regulating CNS metabolism²⁵. With their numerous processes, they are in tight contact with neurons, including motor neurons, and blood vessels. They transport nutrients from the blood stream to neurons and store blood-derived glucose in the form of glycogen as the CNS fuel reserve²⁶ and perhaps also as free glucose in endoplasmic reticulum²⁷. Astrocytes are considered an important cellular target of noradrenaline (NA), released from the locus coeruleus (LC) noradrenergic neurons, which regulates CNS energy metabolism^{28,29,30,31,32}. NA binds to G-protein-coupled adrenergic receptors (ARs; α₁-, α₂- and β-ARs [β₁, β₂, β₃]) on the surface of brain cells, including astrocytes^33,34, where ARs are abundantly expressed³⁵, changing the intracellular concentration of cyclic adenosine monophosphate ([cAMP]_i) and Ca²⁺ ([Ca²⁺]_i)^36,37,38,39. This activates astroglial metabolism, which is mainly controlled by β-AR/cAMP signaling, enhancing glucose uptake, glycogenolysis, aerobic glycolysis, and lactate production⁴⁰. Lactate is considered to be then shuttled to neurons where it is used as fuel by being transformed to pyruvate and entering oxidative phosphorylation^41,42.

In vitro and in vivo studies using ALS model systems of superoxide dismutase 1 (SOD1)-related familial ALS have provided first evidence of metabolic dysfunction in ALS astrocytes, particularly in the transporter responsible for the efflux of lactate⁴³, dysfunctional astrocytic mitochondria⁴⁴, and lower levels of intracellular lactate upon exposure of astrocytes to glutamate⁴⁵. Besides glucose metabolism, lipid metabolism might also be impaired in neurons and astrocytes during neurodegeneration as observed in animal models^46,47,48. If reactive oxygen species (ROS) are elevated in the brain like during neurodegeneration⁴⁶, the glia-neuron lactate shuttle is believed to promote lipid synthesis in neurons. Peroxidized and potentially cytotoxic lipids are then shuttled via apolipoproteins (APO) E and D and fatty acid transport proteins, from neurons to glial cells, causing accumulation of lipid droplets (LDs) in glial cells⁴⁷, dynamic organelles, undergoing regulated, stress-induced biogenesis and/or degradation^49,50, that play an important role in intracellular lipid metabolism and storage⁵¹. Consistent with the observations in animal models, a reduced glucose uptake and increased glycogen storage have been observed in the CNS of patients with ALS⁵²; both processes highly depend on astrocytes, suggesting alterations in astroglial metabolism. Whether TDP-43 inclusions, a hallmark of ALS and FTD-U pathologies, can in astrocytes per se alter astroglial glucose and lipid droplet metabolisms is not known, and was the subject of this study.

The results revealed that overexpression of the C-terminal fragment of TDP-43 (amino acids 208–414) results in cytoplasmic TDP-43 inclusions in cultured rat cortical astrocytes, typical for ALS and FTD-U pathologies. These cells accumulated LDs. To measure the effect of TDP-43 inclusions in single cells on the dynamics of AR-induced Ca²⁺, cAMP signaling and lactate production in astrocytes, we used real-time fluorescence microscopy, Ca²⁺ indicator Fluo-4 AM dye, and genetically encoded FRET (fluorescence resonance energy transfer)-based cAMP (Epac1-camps⁵³) and lactate (Laconic⁵⁴) nanosensors. NA induced increases in [cAMP]_i, [Ca²⁺]_i, and intracellular concentration of lactate ([lactate]_i) in astrocytes expressing wild-type (WT) TDP-43 and in astrocytes with cytoplasmic TDP-43 inclusions (expressing C-terminal fragment of TDP-43). The amplitude and the time constant of the increase in [cAMP]_i were, however, reduced by 35% and 50%, respectively, and the peak amplitude and the cumulative [Ca²⁺]_i increase were reduced by 20% and 30%, respectively, in astrocytes with cytoplasmic TDP-43 inclusions (expressing C-terminal fragment of TDP-43) versus astrocytes transfected with WT TDP-43. The amplitude and the rate of increase in [lactate]_i upon NA treatment were similar in WT TDP-43 expressing astrocytes and in astrocytes with TDP-43 inclusions, however the responsiveness of astrocytes containing cytoplasmic TDP-43 inclusions to NA with production of lactate was increased by 1.6-fold versus WT TDP-43 expressing cells. Astrocytes with TDP-43 inclusions exhibited a reduced expression of β₂-ARs and MCT1 transporters, as determined with immunocytochemistry, consistent with reduced cAMP and Ca²⁺ signaling and suggesting decreased astroglial lactate release capacity. Thus, astroglial aerobic glycolysis is altered in astrocytes with cytoplasmic TDP-43 inclusions, which may affect astroglial metabolic support of neurons in ALS and FTD-U. Moreover, these cells accumulated LDs.

Results

Overexpression of TDP-43^208–414 in astrocytes causes cytoplasmic inclusions and lowers the amount of endogenous nuclear TDP-43

To study how ALS- and FTD-U-associated TDP-43 inclusions in astrocytes affect cell metabolism, in particularly LD and glucose metabolisms, we transfected primary cortical rat astrocytes with the pDNA encoding RFP-tagged C-terminal fragment of TDP-43 (RFP-TDP-43^208–414), known to generate cytoplasmic inclusions in other cell types²⁰, or with the pDNA encoding RFP-tagged WT TDP-43 (RFP-TDP-43^wt). Using confocal microscopy, we observed that in astrocytes expressing the RFP-TDP-43^wt construct, the RFP signal is visible mainly in the cell nucleus (Fig. 1B), whereas in RFP-TDP-43^208–414-expressing astrocytes, red fluorescent inclusions, typical for ALS and FTD-U pathologies, are observed in the cytoplasm (Fig. 1C). To confirm the subcellular localization of the TDP-43 in cultured rat astrocytes after transfection, we immunostained non-transfected (control) cells and cells expressing RFP-TDP-43^wt and RFP-TDP-43^208–414 with antibodies against TDP-43 (Fig. 1). We observed that the red fluorescent regions represent the RFP-tagged TDP-43-containing subcellular compartments, because they largely colocalized with the cell areas labelled with green Alexa Fluor⁴⁸⁸-labelled TDP-43 antibodies. The degree of colocalization (%) with anti-TDP-43 was 71.5 ± 5.5% (n = 20) and 95.5 ± 2.1% (n = 23) in RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes, respectively (Fig. 1D). Since the expression of RFP-TDP-43^wt is disperse and RFP-TDP-43^208–414 is concentrated in inclusions, this complicates the quantitation of expression level of the constructs at cellular level by means of measuring RFP intensity fluorescence signal per total cell area.

Previous studies on different cell types have demonstrated that TDP-43 cytoplasmic inclusions cause nuclear clearance of endogenous TDP-43^5,10,55. Therefore, we next investigated whether expression of the C-terminal fragment of TDP-43 (TDP-43^208–414) affects the nuclear levels of endogenous TDP-43 in cultured rat astrocytes. To evaluate this, we performed colocalization analysis between Alexa⁴⁸⁸-labelled TDP-43 antibody and nuclear marker DAPI in control, non-transfected astrocytes, and in astrocytes expressing the RFP-tagged TDP-43 pDNA constructs. The degree of colocalization (%) with DAPI was 99.1 ± 0.4% (n = 28), 92.2 ± 2.9% (n = 20), and 33.9 ± 6.0% (n = 23) in control, RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes, respectively (Fig. 1E). The relatively low percentage of TDP-43 antibody colocalization with DAPI in astrocytes expressing the RFP-TDP-43^208–414, compared with control, non-transfected and RFP-TDP-43^wt-expressing astrocytes (P < 0.001), suggests that the C-terminal fragment of TDP-43 causes partial depletion of endogenous nuclear TDP-43. When we analyzed the extent of DAPI and TDP-43-colabeled nuclei of non-transfected astrocytes (with no visible RFP signal), positioned around astrocytes expressing the RFP-TDP-43 constructs (with visible RFP signal), we observed a small, statistically insignificant reduction trend in percentage of DAPI and TDP-43-colabeled nuclei in the RFP-TDP-43^208–414 experimental group compared to RFP-TDP-43^wt and control experimental group (Fig. 1F). This suggests that the transfection with the RFP-tagged TDP-43^208–414 construct may affect the endogenous level of nuclear TDP-43 and/or change the antibody staining in some neighboring non-transfected astrocytes.

Taken together, these results demonstrate that in cultured rat astrocytes, expression of the ALS- and FTD-U-linked C-terminal fragment of TDP-43 causes the formation of TDP-43-containing cytoplasmic inclusions and partial sequestration of endogenous nuclear TDP-43 to the cytoplasm.

Lipid droplet content is increased in the cytoplasm of TDP-43^208–414-expressing astrocytes

To evaluate whether the expression of the ALS- and FTD-U-linked C-terminal fragment of TDP-43 affects accumulation of astroglial LDs, we stained non-transfected cells and cells expressing RFP-TDP-43^wt and RFP-TDP-43^208–414 with a fluorescent LD marker BODIPY^493/503 (Fig. 2). The expression of RFP-TDP-43^208–414 (n = 41) in astrocytes increased the amount of BODIPY^493/503-positive cell cross-sectional area, indicating LD content increase, by ~4- and ~3-fold compared with control non-transfected (n = 58) and RFP-TDP-43^wt-expressing astrocytes, respectively (n = 41; Fig. 2B; P < 0.001). Moreover, the average number of LDs per cell (32.0 ± 4.1 (RFP-TDP-43^wt) versus 74.7 ± 6.7 (RFP-TDP-43^208–414), P < 0.001), LD perimeter (1.6 ± 0.1 μm (RFP-TDP-43^wt) versus 2.3 ± 0.1 μm (RFP-TDP-43^208–414), P < 0.001), and LD diameter (0.50 ± 0.02 μm (RFP-TDP-43^wt) versus 0.74 ± 0.03 μm (RFP-TDP-43^208–414), P < 0.001), increased in astrocytes with TDP-43 inclusions (Fig. 2C–E), indicating an increase in the accumulation of LDs.

A small amount of TDP-43 inclusions in some cells can be seen inside the DAPI-labelled nuclear area, thus the role of nuclear TDP-43 inclusions on the accumulation of LDs cannot be excluded. However, since the thickness of the optical section of an individual confocal image was relatively large (1.2 μm) enabling the nuclear and cytosolic fluorescence signals to overlap, it is more likely, that the TDP-43 inclusions seen at the DAPI-labeled nuclear area are in fact located in the cytosol.

Noradrenaline-mediated increases in [cAMP]_i and [Ca²⁺]_i are reduced in TDP-43^208–414-expressing astrocytes

Astrocytes appear to be the primary target of NA, an important neuromodulator in the CNS^28,29,30,40. Through binding to ARs on the surface of astrocytes, NA activates cAMP and Ca²⁺ signaling^37,39,56, which may be dysregulated in various neurologic disorders^{32,57,58,59,60}. To study whether ALS- and FTD-U-linked TDP-43 inclusions affect cAMP and Ca²⁺ signaling, we monitored NA-induced changes in [cAMP]_i and [Ca²⁺]_i using real-time confocal microscopy and genetically encoded FRET-based cAMP nanosensor Epac1-camps⁵³ or Fluo-4 AM dye, respectively, in astrocytes expressing WT (RFP-TDP-43^wt) or mutant TDP-43 pDNA construct (RFP-TDP-43^208–414; Figs. 3 and 4 and Online resource 1, Fig. S1).

The percentage of astrocytes co-expressing both Epac1-camps and RFP-TDP-43^wt or RFP-TDP-43^208–414 construct was 68.4% (n = 54/79) or 44.7% (n = 42/94), respectively (Online resource 1, Fig. S1; Table 1). Only astrocytes that co-expressed Epac1-camps and RFP-TDP-43 pDNA constructs were used in the experiments. The addition of NA (100 µM), a non-selective α-/β-AR agonist, induced an exponential increase in the Epac1-camps FRET signal (CFP/YFP), likely reflecting a β-AR-mediated increase in [cAMP]_i^37,39 in both RFP-TDP-43^wt (n = 9) and RFP-TDP-43^208–414-expressing astrocytes (n = 9; Fig. 3B; Table 2). The mean amplitude change in the FRET signal (mean ΔFRET [%]) and the mean time constant (τ) in astrocytes expressing RFP-TDP-43^wt were 27.1 ± 3.6% and 19.9 ± 2.7 s, respectively (Fig. 3C,D), not significantly different from control, Epac1-camps-expressing astrocytes (Online resource 1, Fig. S2A; P = 0.43 [ΔFRET] and P = 0.63 [τ])³⁷, indicating that the overexpression of RFP-TDP-43^wt and RFP-tagging of the TDP-43^wt does not affect NA-mediated cAMP signals in astrocytes. However, the NA-mediated increase in [cAMP]_i was significantly reduced in RFP-TDP-43^208–414- compared with RFP-TDP-43^wt-expressing astrocytes, as reflected by the reduced amplitude in the FRET signal (~18% versus ~27%, respectively; P < 0.05; Fig. 3C). Similarly, the time constant of the FRET signal increase was significantly slower in RFP-TDP-43^208–414- versus RFP-TDP-43^wt-expressing astrocytes (10.7 ± 1.6 s versus 19.9 ± 2.7 s, respectively; P < 0.05; Fig. 3D). Resting levels of cAMP in RFP-TDP-43^208–414- and RFP-TDP-43^wt-expressing astrocytes were unchanged (not shown). Thus, noradrenergic stimulation leading to the β-AR-mediated increase in [cAMP]_i is reduced in astrocytes expressing the ALS- and FTD-U-related C-terminal fragment of TDP-43 (amino acids 208–414) compared with astrocytes expressing WT TDP-43.

Table 1 The percentage of astrocytes (co)expressing Epac1-camps and RFP-tagged TDP-43 constructs 30 h after transfection of cells with Epac1-camps and either RFP-TDP-43^wt or RFP-TDP-43^208–414 pDNA constructs.

Full size table

Table 2 Responsiveness of astrocytes transfected with RFP-tagged TDP-43 pDNA constructs to noradrenaline- and isoprenaline-induced changes in intracellular cAMP and lactate levels.

Full size table

Next, astrocytes expressing RFP-TDP-43^wt or RFP-TDP-43^208–414 were labeled with Ca²⁺ indicator, Fluo-4 AM dye, and treated with NA (100 µM; Fig. 4). Application of NA elicited rapid increase in Fluo-4 AM fluorescence (ΔF) that after reaching a peak started to decrease towards the baseline level both in RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes (Fig. 4B), reflecting increase in [Ca²⁺]_i likely through activation of α₁-ARs³⁹. The mean peak amplitude and the cumulative Ca²⁺ response were, however, significantly lower in astrocytes expressing RFP-TDP-43^208–414 (3.2 ± 0.3 ΔF/F₀ [RFP-TDP-43^wt; n = 55] versus 2.6 ± 0.2 ΔF/F₀ [RFP-TDP-43^208–414; n = 162; P < 0.05] and 98.5 ± 15.2 ΔF/F₀ [RFP-TDP-43^wt; n = 55] versus 68.1 ± 7.2 ΔF/F₀ [RFP-TDP-43^208–414; n = 162; P < 0.05]; respectively; Fig. 4C,D).

These results show that NA-mediated cAMP and Ca²⁺ signaling are attenuated in astrocytes with ALS- and FTD-U-linked TDP-43 inclusions.

Responsiveness of cells to noradrenaline-induced lactate production was higher in TDP-43^208–414- than in TDP-43^wt-expressing astrocytes

In astrocytes, noradrenergic signaling regulates glucose metabolism, in particular aerobic glycolysis and lactate production^40,61,62, which may be altered in ALS⁵². This may affect astrocyte-neuron lactate shuttle and astrocytic metabolic support of neurons. Because NA-mediated cAMP signaling is reduced in astrocytes overexpressing RFP-TDP-43^208–414, we asked whether RFP-TDP-43^208–414 overexpression affects the NA-mediated increase in aerobic glycolysis and therefore lactate production. To monitor real-time changes in [lactate]_i, upon the addition of NA, cultured rat astrocytes expressing RFP-TDP-43^wt or RFP-TDP-43^208–414 were co-transfected with the FRET-based nanosensor Laconic (Fig. 5)⁵⁴. As in the experiments with Epac1-camps, only astrocytes expressing both Laconic and RFP-TDP-43 pDNA constructs were used in the analysis.

The results revealed that the amplitudes (ΔFRET [%]) and the initial rates of the Laconic FRET signal increase (ΔFRET/Δtime [%/min]) in NA-responsive cells were similar in the RFP-TDP-43^wt- and the RFP-TDP-43^208–414-expressing astrocytes (3.2 ± 0.5% [RFP-TDP-43^wt; n = 9] versus 3.1 ± 0.4% [RFP-TDP-43^208–414; n = 7; P = 0.83] and 1.5 ± 0.4%/min [RFP-TDP-43^wt; n = 9] versus 1.7 ± 0.6%/min [RFP-TDP-43^208–414; n = 7; P = 0.77]; respectively; Fig. 5A, Table 2). In control experiments, in which isolated astrocytes were transfected with Laconic only (no co-transfection with RFP-TDP-43 constructs), stimulation with NA (100 µM) elicited similar increases in [lactate]_i as in astrocytes expressing RFP-TDP-43^wt (Online resource 1, Fig. S2B; n = 7 cells), indicating that overexpression of RFP-TDP-43^wt does not affect the normal glycolytic response in astrocytes.

However, when we looked at the whole population of astrocytes, we observed that the responsiveness of astrocytes to NA-induced lactate production increased by 1.6-fold (from 42.8% to 70.0%) in cells expressing RFP-TDP-43^208–414 compared with astrocytes expressing RFP-TDP-43^wt (Fig. 5C; Table 2), suggesting that the probability of activating aerobic glycolysis in a cell population is facilitated in astrocytes with TDP-43 cytoplasmic inclusions. In control astrocytes expressing only Laconic (no co-transfection with RFP-TDP-43 constructs), the responsiveness of astrocytes to NA-induced lactate production was similar to that in astrocytes expressing RFP-TDP-43^wt (31.8% versus 42.8%, respectively).

When we treated astrocytes with the selective β-AR agonist Iso, the responsiveness of cells was similar (64.0% (RFP-TDP-43^wt) versus 60.0% (RFP-TDP-43^208–414); Table 2, Fig. 5D). The mean amplitude and the initial rate of the Laconic FRET signal increase were 1.6-fold and 2-fold lower, respectively, but statistically insignificantly different, in the RFP-TDP-43^208–414 than in the RFP-TDP-43^wt-expressing astrocytes (2.6 ± 0.5% [RFP-TDP-43^wt; n = 16] versus 1.6 ± 0.2% [RFP-TDP-43^208–414; n = 9; P = 0.2] and 2.2 ± 1.2%/min [RFP-TDP-43^wt; n = 16] versus 1.1 ± 0.1%/min [RFP-TDP-43^208–414; n = 9; P = 0.4]; respectively; Fig. 5B, Table 2).

The overexpression of TDP-43^208–414 reduces the expression of β₂-adrenergic receptors in astrocytes

Because the expression of RFP-TDP-43^208–414 causes a reduction in NA-mediated cAMP and Ca²⁺ signaling compared with cells expressing RFP-TDP-43^wt, we next investigated whether the overexpression of RFP-TDP-43^208–414 alters the expression of ARs. Astrocytes express all types of ARs^33,34,63. We immunostained astrocytes expressing RFP-TDP-43^wt and RFP-TDP-43^208–414 with antibodies against α₁-, β₁-, or β₂-ARs (Fig. 6).

While the expression of α₁- and β₁-ARs was not significantly different between the RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes (84.0% ± 2.0% [n = 40] versus 83.7% ± 1.6% [n = 40; P = 0.63]) and 12.0% ± 1.4% [n = 48] versus 10.0% ± 0.8% [n = 50; P = 0.62], respectively; Fig. 6A,B), the expression of β₂-ARs was significantly lower in astrocytes expressing RFP-TDP-43^208–414 (69.2% ± 8.4% [RFP-TDP-43^wt; n = 41] versus 37.5% ± 8.6% [RFP-TDP-43^208–414; n = 41]; P < 0.001; Fig. 6C). This indicates a downregulation of β₂-ARs in astrocytes expressing the ALS- and FTD-U-linked RFP-TDP-43^208–414 construct, which may contribute to the reduced intracellular cAMP and Ca²⁺ signaling (Figs. 3 and 4) in these cells³⁹.

The expression of MCT1 transporters is reduced in TDP-43^208–414-expressing astrocytes

Since NA-mediated lactate production was enhanced in astrocytes with TDP-43 inclusions (Fig. 5), which may affect the availability of extracellular lactate, we next investigated whether the presence of TDP-43 inclusions alters the expression level of astrocyte-specific monocarboxylate transporters (MCT), which are in astrocytes predominantly responsible for L-lactate transport across the plasma membrane. We immunostained astrocytes expressing RFP-TDP-43^wt and RFP-TDP-43^208–414 with antibodies against MCT1 and MCT4 transporters (Fig. 7). The expression level of MCT4 transporters did not significantly differ between the RFT-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes (7.8% ± 0.9% [n = 47] versus 6.4% ± 0.8% [n = 42; P = 0.25]; Fig. 7B), while the expression of MCT1 transporters was significantly lower in astrocytes expressing RFP-TDP-43^208–414 (4.2% ± 0.5% [n = 45] versus 2.7% ± 0.5% [n = 47; P < 0.01]; Fig. 7A). These results suggest a downregulation of MCT1 transporters in astrocytes with ALS- and FTD-U-linked TDP-43 inclusions, which indicates a decreased astroglial lactate release capacity.

Discussion

Based on the new disease models, a number of recent studies have highlighted the involvement of non-neuronal cells in the pathogenesis of ALS and FTD-U, including astrocytes^2,7, which provide metabolic and trophic support to motor neurons. However, the molecular mechanisms of astroglial-mediated neurotoxicity in ALS and FTD-U remain poorly understood. Here, we investigated whether astroglial expression of the C-terminal fragment of TDP-43 (TDP-43^208–414), a major component of ALS- and FTD-U-associated pathologic cytoplasmic inclusions, affects astroglial cell metabolism. TDP-43 inclusions may compromise astroglial metabolic support of neurons in ALS and FTD-U and contribute to CNS hypometabolism observed in patients with neurodegeneration.

Expression of C-terminal fragment of TDP-43 in isolated cortical rat astrocytes has led to the formation of cytoplasmic TDP-43 inclusions, which can mimic key biochemical features of TDP-43 proteinopathies^10,20, consistent with studies in other cell types^20,64. Astrocytes with cytoplasmic TDP-43 inclusions had a 3-fold lower amount of endogenous nuclear TDP-43 (which may cause a partial loss-of-function of nuclear TDP-43) compared with astrocytes expressing WT TDP-43, where most of the TDP-43 was present in the cell nucleus. This indicates that expression of the C-terminal fragment of TDP-43 in astrocytes affects trafficking of endogenous TDP-43 between the nucleus and the cytoplasm, consistent with reports on neurons⁵, glial cells from human tissue samples⁵⁵, various cell lines (e.g. QBI-293 and tsBN2 cells¹⁰), and muscle cells⁶⁵. The results suggest that aggregated TDP-43 prevents newly synthesized endogenous TDP-43 from being imported into the nucleus and/or inhibits the re-entry of existing cytoplasmic TDP-43 into the nucleus^10,13. Interestingly, the transfection with inclusion-forming TDP-43, caused in neighboring non-transfected astrocytes (with no visible RFP signal) a small, albeit not significant, trend in reduced percentage of DAPI and TDP-43-colabeled nuclei, which suggests that the transfection with the C-terminal fragment of TDP-43 might affect the physiology of non-transfected cells. In pathological conditions, mimicked here by the expression of inclusion-forming TDP-43, astrocytes bear a significant functional plasticity, known as reactive astrogliosis⁶⁶. These astrocytes secrete or distribute through gap junctions various cytotoxic factors, such as Lcn2^22,67,68, interleukin-6, ciliary neurotrophic factor, etc.⁶⁹, which can affect neighboring cells. Even though we did not specifically test whether astrocytes expressing inclusion-forming TDP-43 transform into a reactive phenotype, this outcome is possible. If this is the case, the observed reduction in the nuclear TDP-43 staining in some non-transfected astrocytes adjacent to inclusion-forming TDP-43 astrocytes may be a consequence of altered physiological state of these cells affecting the TDP-43 gene expression level or the synthesis/degradation/distribution of TDP-43.

Because TDP-43 is involved in multiple aspects of RNA processing, any changes in TDP-43 nuclear level may have detrimental effects on astroglial physiology³, including on cell metabolism. LD accumulation has been observed in glial cells, including astrocytes, in early stages of neurodegeneration⁴⁶. Recently, alterations in lipid metabolism (accumulation of cholesteryl esters, determined with lipidomic analysis) in spinal cords from SOD1^G93A transgenic mouse model have been reported that might be linked to astrogliosis and LD formation in astrocytes⁴⁸, since a population of astrocytes isolated from the degenerating spinal cords of the same animal model exhibited significant abundance of LDs as well as autophagic and secretory vesicles, all characteristic features of cellular stress and inflammatory activation⁷⁰. However, the mechanisms leading to increased LD accumulation in astrocytes are poorly understood and may, among others, rely on altered neuronal mitochondrial function and ROS as well as on astrocyte-neuron lactate shuttle⁴⁷, in particular on astroglial lactate-derived lipid production in neurons and transfer of excess lipids in lipoprotein-like particles (ApoE) from neurons to astrocytes^47,71. We show here that in astrocytes with TDP-43 inclusions the LD presence is enhanced (the size and the number of LDs) in the absence of neighboring neurons, suggesting the existence of an alternative astroglial-mediated mechanism triggering accumulation of LDs through altering the balance between biogenesis and degradation of LDs. Accumulation of LDs in astrocytes with cytoplasmic TDP-43 inclusions may be a response to cellular inflammation, which is typically found in the pathology of various neurologic disorders, including ALS^66,72. Here, LDs are hypothesized to be an important source of energy for proliferation and may serve a protective role by gathering free fatty acids to protect cells against lipotoxicity⁷³.

Besides alterations in LD metabolism, changes in noradrenergic regulation of glucose metabolism were observed in astrocytes with cytoplasmic TDP-43 inclusions. Astrocytes with TDP-43 inclusions exhibited downregulation of β₂-ARs and a 35% reduction in NA-mediated increase in [cAMP]_i. Consistent with our results, dysregulation of astrocytic β₂-AR/cAMP signalling has been suspected to contribute to the pathology of a number of other neurologic disorders, including multiple sclerosis, Alzheimer’s disease, human immunodeficiency virus encephalitis, and others⁷⁴. Reduction of β₂-AR expression was reported in human white matter astrocytes obtained from post mortem brain tissue of patients with multiple sclerosis^57,75. Moreover, it was demonstrated both in vitro and in vivo that the presence of Alzheimer’s disease associated amyloid beta peptide (Aβ) in prefrontal cortical neurons leads to internalization and degradation of β₂-ARs, which leads to subsequent attenuation of cAMP signalling⁵⁹. Since aerobic glycolysis in astrocytes is upregulated with β-AR/cAMP signaling, one would expect that astrocytes with TDP-43 inclusions and a reduced expression of β₂-ARs will exhibit reduced β-adrenergic mediated aerobic glycolysis and lactate production. When we stimulated astrocytes with Iso, a selective β-AR agonist, although the responsiveness of cells to Iso was unchanged, there was a trend in reduction of [lactate]_i increase, since the amplitude in [lactate]_i increase was ~2-fold lower (P = 0.08) in astrocytes with TDP-43 inclusions, consistent with downregulation of β₂-AR and cAMP signaling in these cells. In contrast to Iso stimulation, the amplitude and the rate of [lactate]_i increase upon NA stimulation was unaltered in astrocytes with TDP-43 inclusions, but the probability of activating aerobic glycolysis, measured as increased responsiveness to NA, was increased by 1.6-fold in astrocytes with TDP-43 inclusions. When viewing the astroglial population as a whole, this means that glycolytic lactate production upon NA stimulation is facilitated in astrocytes with TDP-43 inclusions.

Besides cAMP, Ca²⁺ signals through activation of α₁-AR/G_q-protein signaling pathway have important role in regulation of NA-mediated glucose metabolism in astrocytes³³. Abnormal Ca²⁺ homeostasis has been observed in astrocytes isolated from SOD1^G93A animals. In particular, excess Ca²⁺ release from ER stores upon purinergic/G_q-protein signaling pathway activation has been reported due to abnormal ER Ca²⁺ accumulation⁷⁶. If such a mechanism exists in astrocytes with TDP-43 inclusions, binding of NA to α₁-AR may lead to excess Ca²⁺-release from ER and enhanced aerobic glycolysis despite downregulation of β₂-AR/cAMP signaling pathway. However, contrary to the results obtained on SOD1^G93A animal model, we observed a 31% reduction in Ca²⁺ signaling in astrocytes with TDP-43 inclusions, even though the level of α₁-AR expression was unchanged. It has been reported that β-AR/cAMP and α₁-AR/Ca²⁺ signaling pathways interact in astrocytes, enhancing each other³⁹, therefore downregulation of β₂-ARs may reduce the noradrenergic Ca²⁺ response via α₁-ARs, explaining the reduction of both noradrenergic cAMP and Ca²⁺ signals despite an unaltered expression of α₁-ARs.

It has been reported that morphologic changes in astrocytes exhibit a bell-shaped dependency on [cAMP]_i³⁷. If aerobic glycolysis in astrocytes displays a similar bell-shaped dependency on [cAMP]_i, astrocytes with reduced β₂-AR/cAMP signalling may actually attain enhanced metabolic responsiveness to noradrenergic stimulation. Moreover, perturbances in TDP-43 may change the transcriptome and proteome of a cell affecting the expression level of enzymes involved in LD metabolism and aerobic glycolysis, as was observed in other cell types with a TDP-43 knock down¹⁶. Whether expression level of metabolic enzymes is altered in astrocytes with TDP-43 inclusions and whether this contributes to the observed enhanced astroglial metabolism needs to be investigated in the future.

Increased lactate production upon NA stimulation in astrocytes with TDP-43 inclusions may lead to a better metabolic support of neurons with lactate due to lactate flux generated between astrocytes and neurons⁷⁷. This is, however, contradictory to the CNS hypometabolism observed in patients with neurodegenerative diseases, including ALS^43,45. Recently, decreased expression of lactate MCT1 and MCT4 transporters has been reported post mortem in the motor cortex of ALS patients compared to non-ALS patients⁷⁸. Moreover, downregulation of MCT1 mRNA in the spinal cords of early symptomatic and endstage SOD1^G93A transgenic mice model of ALS has been observed, presumably in glia (oligodendrocytes and astrocytes)⁷⁸. Down-regulation of the lactate MCT4 transporter has been also demonstrated in spinal cord astrocytes from patients with ALS with SOD1 mutations and in pre-symptomatic SOD1^G93A transgenic mice⁴³. We show here that expression of C-terminal fragment of TDP-43 (TDP-43^208–414) per se in astrocytes causes a reduction in the expression of astroglial lactate MCT1 transporters. Lower expression of astroglial MCTs may decrease the lactate release capacity in astrocytes. Thus, despite facilitated NA-mediated aerobic glycolysis in astrocytes with TDP-43 inclusions, lactate may accumulate inside cells, and the metabolic support of neurons in patients may be decreased significantly contributing to neuron degeneration in ALS and FTD-U. Consistent with this hypothesis, cAMP signaling and lactate homeostasis in the brain were noted to be reduced in patients with some forms of ALS^43,45.

In conclusion, the results of the present study show that expression of the C-terminal fragment of TDP-43 in isolated rat cortical astrocytes leads to the formation of TDP-43-positive cytoplasmic inclusions, a hallmark of ALS. These astrocytes exhibit reduced NA-mediated cAMP and Ca²⁺ signaling, whereas both aerobic glycolysis and LD presence appear facilitated. Although NA-mediated L-lactate production was increased in astrocytes with TDP-43 inclusions, the expression of lactate MCT1 transporters was reduced, suggesting decreased astroglial lactate release capacity (Fig. 8). Thus, these findings reflect an astroglial stressed state that may fail to adequately metabolically support neurons in ALS and FTD-U, leading to neurotoxicity.

Methods

Cell culture and transfection

Unless noted otherwise, all chemicals were of the highest quality available and purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Primary astrocyte cultures were prepared from the cerebral cortices of 2- to 3-day-old Wistar rats, as described previously⁷⁹, and grown in high-glucose Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM l-glutamine and 25 µg/ml penicillin-streptomycin in a vaporized atmosphere containing 95% air and 5% CO₂ at 37 °C until reaching 70%–80% confluence. Confluent cultures were shaken overnight at 225 rpm and the medium was changed the next morning; this was repeated three times. After the third overnight shaking, the cells were trypsinized and put in flat tissue culture tubes with 10 cm² growth area. After reaching confluence again, the cells were subcultured onto 22-mm diameter poly-l-lysine-coated glass coverslips. This procedure yielded astrocytes with > 95% purity, determined by anti-glial fibrillary acidic protein (GFAP) antibody staining⁸⁰.

After 1–3 days, astrocytes were co-transfected with the genetically encoded FRET-based cAMP nanosensor Epac1-camps⁵³ or lactate nanosensor Laconic⁵⁴ and RFP-tagged WT TDP-43 (pTagRFP-C::TDP-43^wt [RFP-TDP-43^wt]) or RFP-tagged C-terminal fragment of TDP-43 (pTagRFP-C::TDP-43^208–414 [RFP-TDP-43^208–414]) using FuGENE 6 Transfection Reagent (Promega Corporation, Madison, WI, USA). Transfection medium contained no serum or antibiotics.

The experimental animals were cared for in accordance with the International Guiding Principles for Biomedical Research Involving Animals developed by the Council for International Organizations of Medical Sciences and the Animal Protection Act (Official Gazette RS, no. 38/13). The experimental protocol was approved by The Administration of the Republic of Slovenia for Food Safety, Veterinary and Plant Protection (Republic of Slovenia, Ministry of Agriculture, Forestry and Food, Dunajska cesta 22, 1000 Ljubljana), Document No. U34401-47/2014/7, signed by Barbara Tomše, DVM. Every set of data was acquired from at least 2 independent experiments.

Immunocytochemistry and data analysis

Control (non-transfected) astrocytes and astrocytes expressing RFP-TDP-43^wt or RFP-TDP-43^208–414 were fixed with 4% formaldehyde in phosphate buffered saline (PBS) for 15 min and then permeabilized with 0.1% Triton X-100 for 10 min at room temperature (except for MCT1 and MCT4) before being treated with 10% goat serum for 1 h at 37 °C. Astrocytes were then stained with primary antibodies against endogenous TDP-43 (C-terminal, rabbit polyclonal, 1:400; Proteintech, Manchester, UK), α₁-AR (rabbit polyclonal, 1:100; Abcam, Cambridge, UK), β₁-AR (rabbit polyclonal, 1:200; Abcam, Cambridge, UK), β₂-AR (rabbit polyclonal, 1:100; Biorbyt, Cambridge, UK), MCT1 (rabbit polyclonal, 1:50; Abcam, Cambridge, UK) and MCT4 (rabbit polyclonal, 1:50; Santa Cruz, Texas, US) overnight at 4 °C. After washing with PBS, cells were incubated for 1 h at 37 °C with Alexa Fluor⁴⁸⁸-conjugated secondary goat anti-rabbit IgG (1:600; Abcam, Cambridge, UK). Excess antibodies were washed off and the coverslips were mounted onto glass slides using SlowFade antifade reagent with DAPI (Molecular Probes by Life Technologies, Thermo Fisher Scientific, Massachusetts, USA) and carefully sealed. Immunolabelled cells were imaged with an inverted Zeiss LSM780 confocal microscope with a Plan apochromatic 40×/1.4 oil immersion objective (Carl Zeiss, Jena, Germany) using 488-nm Ar-ion, 543-nm He-Ne and 405-nm diode laser excitation. Emission spectra were acquired sequentially with 505- to 530-nm bandpass (Alexa Fluor⁴⁸⁸), 560-nm long pass (TagRFP⁵⁸⁴) and 445- to 450-nm bandpass (DAPI) emission filters.

Colocalization analysis of Alexa Fluor⁴⁸⁸ (immunolabelled TDP-43), TagRFP⁵⁸⁴ (RFP-TDP-43 pDNA constructs), and DAPI fluorescence signals was performed on exported TIFF files using ColocAna software (Celica Biomedical, Ljubljana, Slovenia)⁸¹ that counts all red, green, blue and colocalized (green and red or green and blue) pixels within the image. The threshold for the colocalized pixel count was set at 20% of the maximal green, red or blue fluorescence intensity, respectively. Colocalization was expressed as the ratio of colocalized to green or blue pixels (as percentages). Kruskal-Wallis one-way analysis of variance (ANOVA) on ranks (followed by Dunn’s test) or Mann-Whitney U test were performed to determine statistical significance between the experimental groups. P < 0.05 was considered significant.

To determine the expression level of different ARs and MCTs, the number of α₁-AR-, β₁-AR-, β₂-AR-, MCT1- and MCT4-positive green fluorescence pixels with fluorescence intensity above the threshold of 10% (α₁-/β₁-/β₂-AR-positive cell area) or 20% (MCT1 and MCT4-positive cell area) of maximal fluorescence and the number of all pixels (total cell area) per cell cross-sectional area were determined for each cell separately in RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes using ZEN software (Zeiss, Oberkochen, Germany). The percentage of the AR- and MCT-positive cell area relative to the total cell area was calculated for RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes for individual receptor and transporter type. The Mann-Whitney U test was performed to determine statistical significance between the experimental groups. P < 0.05 was considered significant.

To determine the extent of DAPI and TDP-43-colabeled nuclei in non-transfected astrocytes (with no visible RFP signal) adjacent to the RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes (with visible RFP signal) we measured the percentage of DAPI and TDP-43-colabeled nuclei per all DAPI nuclei in neighboring non-transfected cells (with no visible RFP signal) in the RFP-TDP-43^wt and RFP-TDP-43^208–414 experimental groups. In the control non-transfected group, we analyzed the nuclei of all cells. Some partially visible DAPI-stained nuclei at the edges of the confocal images were also taken into account in the analysis, however, only if no RFP signal in or around the visible part of the nuclei was observed. Kruskal-Wallis one-way ANOVA on ranks, followed by Dunn’s test was performed to determine statistical significance between the experimental groups. P < 0.05 was considered significant.

Lipid droplet staining and data analysis

Control (non-transfected) astrocytes and astrocytes transfected with RFP-TDP-43^wt or RFP-TDP-43^208–414 plasmid were incubated in fresh growth medium for 24 h. Cells were then fixed in 4% formaldehyde in PBS for 5 min and stained with 1 µg/ml BODIPY^493/503 (Molecular Probes by Life Technologies, Thermo Fisher Scientific, Massachusetts, USA), a fluorescent LD marker, for 6 min at room temperature. Excess dye was washed off and the coverslips were mounted onto glass slides using SlowFade antifade reagent with DAPI (Molecular Probes by Life Technologies, Thermo Fisher Scientific, Massachusetts, USA) and carefully sealed. Stained cells were imaged with an inverted Zeiss LSM780 confocal microscope with a Plan apochromatic 40×/1.4 oil immersion objective (Carl Zeiss, Jena, Germany) using 488-nm Ar-ion, 543-nm He-Ne and 405-nm diode laser excitation. Emission spectra were acquired sequentially with 505- to 530-nm bandpass (BODIPY^493/503), 560-nm long pass (TagRFP⁵⁸⁴) and 445- to 450-nm bandpass (DAPI) emission filters.

To determine the LD content in individual astrocytes, the number of BODIPY^493/503-positive green fluorescence pixels with fluorescence intensity above the threshold of 20% of maximal fluorescence (Lipid droplet S) and the number of all pixels (Cell S) were determined for each cell separately in control, RFP-TDP-43^wt- and RFP-TDP-43^208–414-expressing astrocytes in ZEN software (Zeiss, Oberkochen, Germany). The values obtained were normalized to the average LD content in control non-transfected cells. The mean number of BODIPY^493/503-labeled LDs per cell and the mean LD perimeter were determined in cross-sections of individual cells using ImageJ, Analyze Particles function after applying 20% threshold and signal intensity (watershed) segmentation on individual images. Then, assuming that all LDs are spherical, the mean LD diameter was estimated from the perimeter values with the equation d = C/π, where d is the diameter and C is the LD perimeter. Kruskal-Wallis one-way ANOVA on ranks, followed by Dunn’s test was performed to determine statistical significance between the groups. P < 0.05 was considered significant.

FRET measurements of intracellular cAMP and lactate levels and data analysis

Cells co-expressing the FRET-based nanosensor Epac1-camps or Laconic and RFP-tagged TDP-43 pDNA construct (RFP-TDP-43^wt or RFP-TDP-43^208–414) were examined 24–30 h after transfection with a fluorescence microscope Zeiss Axio Obsever.A1 (Zeiss, Oberkochen, Germany), with a CCD camera and monochromator Polychrome V (Till Photonics, Graefelfing, Germany) as a monochromatic source of light with a wavelength 436 nm/10 nm. Dual emission intensity ratios were recorded using an image splitter (Optical Insights, Tucson, AZ, USA) and two emission filters (465/30 nm for CFP [cyan fluorescent protein] or mTFP [monomeric teal fluorescent protein] and 535/30 nm for YFP [yellow fluorescent protein] or Venus). Images were acquired every 3.5 s for Epac1-camps and 10 s for Laconic. Exposure time was 100 ms.

In some experiments astrocytes co-expressing Laconic and RFP-TDP-43^wt or RFP-TDP-43^208–414 were examined 24 h after transfection with a fluorescence microscope (Zeiss Axio Observer.A1 (Zeiss, Oberkochen, Germany)) with a Axiocam 702 camera and Colibri.2 Lamp Module (Zeiss, Oberkochen, Germany) as a source of light with a wavelength 433 nm. Dual emission intensity ratios were recorded using an image splitter (Optical Insights, Tucson, AZ, USA) and two emission filters (469-491 nm for ECFP and 530-4095 nm for EYFP). Images were acquired at intervals of 10 s with exposure time of 100 ms.

Coverslips with transfected astrocytes were mounted in a superfusion recording chamber on the microscope stage. Imaging was performed at room temperature (22–24 °C). One cell per experiment was recorded. The FRET signals (CFP/YFP (Epac1-camps) and mTFP/Venus (Laconic) signals) were obtained from the integration of the ratio signal over the entire cell using Life Acquisition software (Till Photonics, Graefelfing, Germany) or ZEN (Carl Zeiss, Jena, Germany). In the graphs, the FRET signal was reported as the ratio of the CFP/YFP (Epac1-camps) and mTFP/Venus (Laconic) fluorescence signals after subtracting the background fluorescence from the individual fluorescence signals using Excel (Microsoft, Seattle, WA, USA). The values of the FRET ratio signals were normalized to 1.0. An increase in the FRET ratio signal reflects an increase in [cAMP]_i or [lactate]_i.

Before the experiments, astrocytes were kept in extracellular solution containing sodium bicarbonate for 10 min (10 mM Hepes/NaOH [pH 7.2], 3 mM d-glucose, 135.3 mM NaCl, 1.8 mM CaCl₂, 2 mM MgCl₂, and 5 mM KCl, 0.5 mM NaH₂PO₄·H₂O, 5 mM NaHCO₃), and then treated with 100 µM NA (non-selective AR agonist) or 100 µM Iso (selective β-AR agonist) following a 100- to 200-s baseline. Experiments were conducted with the addition of a bolus solution; 200 µl of extracellular solution containing NA was added by pipette to 200 µl of bath solution in the recording chamber. The application of a control bolus solution without reagents had no significant effect on the FRET signal, as reported previously^82,83. Extracellular solution osmolality was 295–305 mOsm, measured with the Osmomat 030 freezing point osmometer (Gonotech GmbH, Germany).

In experiments with Epac1-camps, single-exponential increases to maximum functions (F = F₀ + c × (1 − exp(−t/τ))) were fitted to the FRET ratio signals using SigmaPlot. The time constant (τ) and amplitude changes in the FRET ratio signal (ΔFRET [%]) were determined from the fitted curves. F is the FRET ratio signal at time t, F₀ is the baseline FRET ratio signal, c is the FRET ratio signal amplitude of F − F₀, and τ is the time constant of the individual exponential component. In experiments with Laconic, the maximal (initial) rates of the FRET ratio signal increase (ΔFRET/Δt) were calculated as the slope of the linear regression function (ΔFRET [%] = slope [%/min] × Δt [min]) fitting the initial FRET ratio signal increase. In these experiments, changes in the FRET ratio signal (ΔFRET [%]) were calculated by subtracting the mean maximal FRET ratio signals from the mean baseline FRET ratio signals.

Unless stated otherwise, the Student’s t-test was performed to determine statistical significance between the experimental groups; P < 0.05 was considered significant.

Fluo-4 AM measurements of cytosolic Ca²⁺ and data analysis

Astrocytes expressing RFP-TDP-43^wt or RFP-TDP-43^208–414 were incubated for 30 min at room temperature in medium containing 2 µM Fluo-4 AM dye (Molecular Probes, Invitrogen) and then transferred to dye-free medium for at least 30 min before the experiments to allow for cleavage of the AM ester group. The cells were excited with an Argon-ion laser at 488 nm, and time-lapse images were obtained every 3 s with an inverted Zeiss LSM780 confocal microscope and an 20x objective. Emission light was acquired with a 505–530-nm band-pass emission filter. Fluo-4 AM–labeled astrocytes were after 100 s baseline stimulated with 100 μM NA. Total recording time was ~400 s (135 frames). In individual cells, Fluo-4 AM intensity was quantified within a region of interest and expressed as the relative change in fluorescence: ΔF/F₀ = (F − F₀)/F₀, where F₀ denotes the baseline fluorescence level after subtraction of background fluorescence. The peak and cumulative increase in Fluo-4 AM ΔF/F₀ were determined using Microsoft Excel.

Mann-Whitney U test was performed to determine statistical significance between the experimental groups. P < 0.05 was considered significant.

Data availability

All data generated or analyzed during this study are included in this published article and its Supplementary Information files or are available from the corresponding author on reasonable request.

References

Hardiman, O. et al. Amyotrophic lateral sclerosis. Nature reviews. Disease primers 3, 17071, https://doi.org/10.1038/nrdp.2017.71 (2017).
Article PubMed Google Scholar
Peters, O. M., Ghasemi, M. & Brown, R. H. Jr. Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest. 125, 1767–1779, https://doi.org/10.1172/jci71601 (2015).
Article PubMed PubMed Central Google Scholar
Lee, E. B., Lee, V. M. & Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38–50, https://doi.org/10.1038/nrn3121 (2011).
Article CAS PubMed PubMed Central Google Scholar
Radford, R. A. et al. The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front. Cell. Neurosci. 9, 414, https://doi.org/10.3389/fncel.2015.00414 (2015).
Article CAS PubMed PubMed Central Google Scholar
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133, https://doi.org/10.1126/science.1134108 (2006).
Article CAS ADS PubMed Google Scholar
Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602–611, https://doi.org/10.1016/j.bbrc.2006.10.093 (2006).
Article CAS PubMed Google Scholar
Sloan, S. A. & Barres, B. A. Glia as primary drivers of neuropathology in TDP-43 proteinopathies. Proc. Natl. Acad. Sci. USA 110, 4439–4440, https://doi.org/10.1073/pnas.1301608110 (2013).
Article ADS PubMed PubMed Central Google Scholar
Chen-Plotkin, A. S., Lee, V. M. & Trojanowski, J. Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6, 211–220, https://doi.org/10.1038/nrneurol.2010.18 (2010).
Article CAS PubMed PubMed Central Google Scholar
Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668–1672, https://doi.org/10.1126/science.1154584 (2008).
Article CAS ADS PubMed PubMed Central Google Scholar
Winton, M. J. et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 283, 13302–13309, https://doi.org/10.1074/jbc.M800342200 (2008).
Article CAS PubMed PubMed Central Google Scholar
Smethurst, P., Sidle, K. C. & Hardy, J. Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol. Appl. Neurobiol. 41, 578–597, https://doi.org/10.1111/nan.12206 (2015).
Article CAS PubMed Google Scholar
Nishimura, A. L. et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763–1771, https://doi.org/10.1093/brain/awq111 (2010).
Article PubMed Google Scholar
Prpar Mihevc, S. et al. Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain 140, 13–26, https://doi.org/10.1093/brain/aww197 (2017).
Article PubMed Google Scholar
Taylor, J. P., Brown, R. H. & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206, https://doi.org/10.1038/nature20413 (2016).
Article ADS PubMed PubMed Central Google Scholar
Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 14, 452–458, https://doi.org/10.1038/nn.2778 (2011).
Article CAS PubMed PubMed Central Google Scholar
Štalekar, M. et al. Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport. Neuroscience 293, 157–170, https://doi.org/10.1016/j.neuroscience.2015.02.046 (2015).
Article CAS PubMed Google Scholar
Prpar Mihevc, S., Baralle, M., Buratti, E. & Rogelj, B. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep 6, 33996, https://doi.org/10.1038/srep33996 (2016).
Article CAS ADS PubMed PubMed Central Google Scholar
Buratti, E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets 22, 279–293, https://doi.org/10.1080/14728222.2018.1439923 (2018).
Article CAS PubMed Google Scholar
Scotter, E. L. et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 127, 1263–1278, https://doi.org/10.1242/jcs.140087 (2014).
Article CAS PubMed PubMed Central Google Scholar
Igaz, L. M. et al. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J. Biol. Chem. 284, 8516–8524, https://doi.org/10.1074/jbc.M809462200 (2009).
Article CAS PubMed PubMed Central Google Scholar
Yamanaka, K. & Komine, O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 126, 31–38, https://doi.org/10.1016/j.neures.2017.09.011 (2018).
Article CAS PubMed Google Scholar
Tong, J. et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 32, 1917–1926, https://doi.org/10.1038/emboj.2013.122 (2013).
Article CAS PubMed PubMed Central Google Scholar
Rojas, F., Cortes, N., Abarzua, S., Dyrda, A. & van Zundert, B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front. Cell. Neurosci. 8, 24, https://doi.org/10.3389/fncel.2014.00024 (2014).
Article CAS PubMed PubMed Central Google Scholar
Oberheim, N. A., Goldman, S. A. & Nedergaard, M. Heterogeneity of astrocytic form and function. Methods Mol Biol 814, 23–45, https://doi.org/10.1007/978-1-61779-452-0_3 (2012).
Article CAS PubMed PubMed Central Google Scholar
Verkhratsky, A. & Nedergaard, M. Physiology of Astroglia. Physiol. Rev. 98, 239–389, https://doi.org/10.1152/physrev.00042.2016 (2018).
Article CAS PubMed Google Scholar
Barros, L. F. Metabolic signaling by lactate in the brain. Trends Neurosci 36, 396–404, https://doi.org/10.1016/j.tins.2013.04.002 (2013).
Article CAS PubMed Google Scholar
Müller, M. S., Fouyssac, M. & Taylor, C. W. Effective Glucose Uptake by Human Astrocytes Requires Its Sequestration in the Endoplasmic Reticulum by Glucose-6-Phosphatase-β. Curr Biol 28, 3481–3486.e3484, https://doi.org/10.1016/j.cub.2018.08.060 (2018).
Article CAS PubMed PubMed Central Google Scholar
Ding, F. et al. α1-Adrenergic receptors mediate coordinated Ca2+ signaling of cortical astrocytes in awake, behaving mice. Cell Calcium 54, 387–394, https://doi.org/10.1016/j.ceca.2013.09.001 (2013).
Article CAS PubMed Google Scholar
Bekar, L. K., He, W. & Nedergaard, M. Locus coeruleus alpha-adrenergic-mediated activation of cortical astrocytes in vivo. Cereb Cortex 18, 2789–2795, https://doi.org/10.1093/cercor/bhn040 (2008).
Article PubMed PubMed Central Google Scholar
Paukert, M. et al. Norepinephrine controls astroglial responsiveness to local circuit activity. Neuron 82, 1263–1270, https://doi.org/10.1016/j.neuron.2014.04.038 (2014).
Article CAS PubMed PubMed Central Google Scholar
Dienel, G. A. & Cruz, N. F. Aerobic glycolysis during brain activation: adrenergic regulation and influence of norepinephrine on astrocytic metabolism. J Neurochem 138, 14–52, https://doi.org/10.1111/jnc.13630 (2016).
Article CAS PubMed Google Scholar
Zorec, R., Parpura, V. & Verkhratsky, A. Preventing neurodegeneration by adrenergic astroglial excitation. FEBS J, https://doi.org/10.1111/febs.14456 (2018).
Hertz, L., Lovatt, D., Goldman, S. A. & Nedergaard, M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem. Int. 57, 411–420, https://doi.org/10.1016/j.neuint.2010.03.019 (2010).
Article CAS PubMed PubMed Central Google Scholar
Hertz, L., Chen, Y., Gibbs, M. E., Zang, P. & Peng, L. Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders? Curr. Drug Targets CNS Neurol. Disord. 3, 239–267 (2004).
Article CAS PubMed Google Scholar
Aoki, C. Beta-adrenergic receptors: astrocytic localization in the adult visual cortex and their relation to catecholamine axon terminals as revealed by electron microscopic immunocytochemistry. J Neurosci 12, 781–792 (1992).
Article CAS PubMed PubMed Central Google Scholar
Vardjan, N. & Zorec, R. Excitable Astrocytes: Ca(2+)- and cAMP-Regulated Exocytosis. Neurochem. Res., https://doi.org/10.1007/s11064-015-1545-x (2015).
Vardjan, N., Kreft, M. & Zorec, R. Dynamics of β-adrenergic/cAMP signaling and morphological changes in cultured astrocytes. Glia 62, 566–579, https://doi.org/10.1002/glia.22626 (2014).
Article PubMed Google Scholar
Horvat, A. & Vardjan, N. Astroglial cAMP signalling in space and time. Neurosci Lett, https://doi.org/10.1016/j.neulet.2018.06.025 (2018).
Horvat, A., Zorec, R. & Vardjan, N. Adrenergic stimulation of single rat astrocytes results in distinct temporal changes in intracellular Ca(2+) and cAMP-dependent PKA responses. Cell Calcium 59, 156–163 (2016).
Article CAS PubMed Google Scholar
O’Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S. & Nedergaard, M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 37, 2496–2512, https://doi.org/10.1007/s11064-012-0818-x (2012).
Article CAS PubMed PubMed Central Google Scholar
Magistretti, P. J. & Allaman, I. A cellular perspective on brain energy metabolism and functional imaging. Neuron 86, 883–901, https://doi.org/10.1016/j.neuron.2015.03.035 (2015).
Article CAS PubMed Google Scholar
Magistretti, P. J. & Allaman, I. Lactate in the brain: from metabolic end-product to signalling molecule. Nat Rev Neurosci 19, 235–249, https://doi.org/10.1038/nrn.2018.19 (2018).
Article CAS PubMed Google Scholar
Ferraiuolo, L. et al. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134, 2627–2641, https://doi.org/10.1093/brain/awr193 (2011).
Article PubMed PubMed Central Google Scholar
Cassina, P. et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci 28, 4115–4122, https://doi.org/10.1523/JNEUROSCI.5308-07.2008 (2008).
Article CAS PubMed PubMed Central Google Scholar
Madji Hounoum, B. et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia 65, 592–605, https://doi.org/10.1002/glia.23114 (2017).
Article PubMed Google Scholar
Liu, L. et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160, 177–190, https://doi.org/10.1016/j.cell.2014.12.019 (2015).
Article CAS PubMed PubMed Central Google Scholar
Liu, L., MacKenzie, K. R., Putluri, N., Maletic-Savatic, M. & Bellen, H. J. The Glia-Neuron Lactate Shuttle and Elevated ROS Promote Lipid Synthesis in Neurons and Lipid Droplet Accumulation in Glia via APOE/D. Cell Metab. 26, 719–737.e716, https://doi.org/10.1016/j.cmet.2017.08.024 (2017).
Article CAS PubMed PubMed Central Google Scholar
Chaves-Filho, A. B. et al. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep 9, 11642, https://doi.org/10.1038/s41598-019-48059-7 (2019).
Article CAS ADS PubMed PubMed Central Google Scholar
Kis, V., Barti, B., Lippai, M. & Sass, M. Specialized Cortex Glial Cells Accumulate Lipid Droplets in Drosophila melanogaster. PLoS One 10, e0131250, https://doi.org/10.1371/journal.pone.0131250 (2015).
Article CAS PubMed PubMed Central Google Scholar
Henne, W. M., Reese, M. L. & Goodman, J. M. The assembly of lipid droplets and their roles in challenged cells. EMBO J 37, https://doi.org/10.15252/embj.201898947 (2018).
Thiam, A. R., Farese, R. V. & Walther, T. C. The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol 14, 775–786, https://doi.org/10.1038/nrm3699 (2013).
Article CAS PubMed PubMed Central Google Scholar
Vandoorne, T. & De Bock, K. & Van Den Bosch, L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol 135, 489–509, https://doi.org/10.1007/s00401-018-1835-x (2018).
Article CAS PubMed PubMed Central Google Scholar
Nikolaev, V. O., Bünemann, M., Hein, L., Hannawacker, A. & Lohse, M. J. Novel single chain cAMP sensors for receptor-induced signal propagation. The Journal of Biological Chemistry 279, 37215–37218, https://doi.org/10.1074/jbc.C400302200 (2004).
Article CAS PubMed Google Scholar
San Martin, A. et al. A genetically encoded FRET lactate sensor and its use to detect the Warburg effect in single cancer cells. PLoS One 8, e57712, https://doi.org/10.1371/journal.pone.0057712 (2013).
Article CAS ADS PubMed PubMed Central Google Scholar
Geser, F. et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch. Neurol. 65, 636–641, https://doi.org/10.1001/archneur.65.5.636 (2008).
Article PubMed Google Scholar
Salm, A. K. & McCarthy, K. D. Norepinephrine-evoked calcium transients in cultured cerebral type 1 astroglia. Glia 3, 529–538, https://doi.org/10.1002/glia.440030612 (1990).
Article CAS PubMed Google Scholar
De Keyser, J., Wilczak, N., Leta, R. & Streetland, C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 53, 1628–1633 (1999).
Article PubMed Google Scholar
Yu, J. T. et al. Roles of beta-adrenergic receptors in Alzheimer’s disease: implications for novel therapeutics. Brain Res. Bull. 84, 111–117, https://doi.org/10.1016/j.brainresbull.2010.11.004 (2011).
Article CAS ADS PubMed Google Scholar
Wang, D., Yuen, E. Y., Zhou, Y., Yan, Z. & Xiang, Y. K. Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J. Biol. Chem. 286, 31852–31863, https://doi.org/10.1074/jbc.M111.244335 (2011).
Article CAS PubMed PubMed Central Google Scholar
Fujita, M. et al. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Mol Psychiatry 22, 754–759, https://doi.org/10.1038/mp.2016.171 (2017).
Article CAS PubMed Google Scholar
Gibbs, M. E., Hutchinson, D. S. & Summers, R. J. Noradrenaline release in the locus coeruleus modulates memory formation and consolidation; roles for α- and β-adrenergic receptors. Neuroscience 170, 1209–1222, https://doi.org/10.1016/j.neuroscience.2010.07.052 (2010).
Article CAS PubMed Google Scholar
Hertz, L. et al. Brain glycogenolysis, adrenoceptors, pyruvate carboxylase, Na(+), K(+)-ATPase and Marie E. Gibbs’ pioneering learning studies. Front. Integr. Neurosci. 7, 1–7, https://doi.org/10.3389/fnint.2013.00020 (2013).
Article CAS Google Scholar
Atkinson, B. N. & Minneman, K. P. Multiple adrenergic receptor subtypes controlling cyclic AMP formation: comparison of brain slices and primary neuronal and glial cultures. J. Neurochem. 56, 587–595 (1991).
Article CAS PubMed Google Scholar
Zhang, Y. J. et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA 106, 7607–7612, https://doi.org/10.1073/pnas.0900688106 (2009).
Article ADS PubMed PubMed Central Google Scholar
Greenberg, S. A., Watts, G. D., Kimonis, V. E., Amato, A. A. & Pinkus, J. L. Nuclear localization of valosin-containing protein in normal muscle and muscle affected by inclusion-body myositis. Muscle Nerve 36, 447–454, https://doi.org/10.1002/mus.20823 (2007).
Article CAS PubMed Google Scholar
Pekny, M. et al. Astrocytes: a central element in neurological diseases. Acta Neuropathol. 131, 323–345, https://doi.org/10.1007/s00401-015-1513-1 (2016).
Article CAS PubMed Google Scholar
Bi, F. et al. Reactive astrocytes secrete lcn2 to promote neuron death. Proc. Natl. Acad. Sci. USA 110, 4069–4074, https://doi.org/10.1073/pnas.1218497110 (2013).
Article ADS PubMed PubMed Central Google Scholar
Lee, S. et al. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J. Neurosci. 29, 234–249, https://doi.org/10.1523/jneurosci.5273-08.2009 (2009).
Article CAS PubMed PubMed Central Google Scholar
Escartin, C. & Bonvento, G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol. Neurobiol. 38, 231–241, https://doi.org/10.1007/s12035-008-8043-y (2008).
Article CAS PubMed Google Scholar
Jiménez-Riani, M. et al. Ultrastructural features of aberrant glial cells isolated from the spinal cord of paralytic rats expressing the amyotrophic lateral sclerosis-linked SOD1G93A mutation. Cell Tissue Res 370, 391–401, https://doi.org/10.1007/s00441-017-2681-1 (2017).
Article CAS PubMed Google Scholar
Ioannou, M. S. et al. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity. Cell 177, 1522–1535.e1514, https://doi.org/10.1016/j.cell.2019.04.001 (2019).
Article CAS PubMed Google Scholar
Liddelow, S. A. & Barres, B. A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity 46, 957–967, https://doi.org/10.1016/j.immuni.2017.06.006 (2017).
Article CAS PubMed Google Scholar
Bozza, P. T. & Viola, J. P. Lipid droplets in inflammation and cancer. Prostaglandins Leukot. Essent. Fatty Acids 82, 243–250, https://doi.org/10.1016/j.plefa.2010.02.005 (2010).
Article CAS PubMed Google Scholar
Laureys, G. et al. Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog Neurobiol 91, 189–199, https://doi.org/10.1016/j.pneurobio.2010.01.011 (2010).
Article CAS PubMed Google Scholar
De Keyser, J., Zeinstra, E. & Wilczak, N. Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol. Dis. 15, 331–339, https://doi.org/10.1016/j.nbd.2003.10.012 (2004).
Article CAS PubMed Google Scholar
Kawamata, H. et al. Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis. J Neurosci 34, 2331–2348, https://doi.org/10.1523/JNEUROSCI.2689-13.2014 (2014).
Article CAS PubMed PubMed Central Google Scholar
Pellerin, L. & Magistretti, P. J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91, 10625–10629, https://doi.org/10.1073/pnas.91.22.10625 (1994).
Article CAS ADS PubMed PubMed Central Google Scholar
Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448, https://doi.org/10.1038/nature11314 (2012).
Article CAS ADS PubMed PubMed Central Google Scholar
Schwartz, J. & Wilson, D. Preparation and characterization of type 1 astrocytes cultured from adult rat cortex, cerebellum, and striatum. Glia 5, 75–80 (1992).
Article CAS PubMed Google Scholar
Vardjan, N. et al. Adrenergic activation attenuates astrocyte swelling induced by hypotonicity and neurotrauma. Glia 64, 1034–1049, https://doi.org/10.1002/glia.22981 (2016).
Article PubMed PubMed Central Google Scholar
Kreft, M., Milisav, I., Potokar, M. & Zorec, R. Automated high through-put colocalization analysis of multichannel confocal images. Comput Methods Programs Biomed 74, 63–67 (2004).
Article CAS PubMed Google Scholar
Prebil, M., Vardjan, N., Jensen, J., Zorec, R. & Kreft, M. Dynamic monitoring of cytosolic glucose in single astrocytes. Glia 59, 903–913, https://doi.org/10.1002/glia.21161 (2011).
Article PubMed Google Scholar
Vardjan, N. et al. Enhancement of Astroglial Aerobic Glycolysis by Extracellular Lactate-Mediated Increase in cAMP. Front Mol Neurosci 11, 148, https://doi.org/10.3389/fnmol.2018.00148 (2018).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

The authors thank Dr. M. Lohse for providing Epac1-camps, Dr. L.F. Barros for providing Laconic, and Drs. Eva Lasič and Marko Kreft for support. The authors’ work was supported by grants from the Slovenian Research Agency (P3-0310, P4-0127, J3-6790, J3-6789, J3-8201, J3 7605, J3-9266) and COST Action CA18133 (ERNEST) and COST Action BM1402 (MouseAGE).

Author information

These authors contributed equally: Jelena Velebit and Anemari Horvat.

Authors and Affiliations

Laboratory of Cell Engineering, Celica Biomedical, 1000, Ljubljana, Slovenia
Jelena Velebit, Anemari Horvat, Robert Zorec & Nina Vardjan
Laboratory of Neuroendocrinology – Molecular Cell Physiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia
Anemari Horvat, Tina Smolič, Robert Zorec & Nina Vardjan
Department of Biotechnology, Jožef Stefan Institute, 1000, Ljubljana, Slovenia
Sonja Prpar Mihevc & Boris Rogelj
Biomedical Research Institute BRIS, 1000, Ljubljana, Slovenia
Boris Rogelj
Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000, Ljubljana, Slovenia
Boris Rogelj

Authors

Jelena Velebit
View author publications
You can also search for this author in PubMed Google Scholar
Anemari Horvat
View author publications
You can also search for this author in PubMed Google Scholar
Tina Smolič
View author publications
You can also search for this author in PubMed Google Scholar
Sonja Prpar Mihevc
View author publications
You can also search for this author in PubMed Google Scholar
Boris Rogelj
View author publications
You can also search for this author in PubMed Google Scholar
Robert Zorec
View author publications
You can also search for this author in PubMed Google Scholar
Nina Vardjan
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

JV performed experiments, analysed data, prepared figures and wrote the manuscript, AH performed experiments, analysed data, prepared figures and wrote the manuscript, TS performed experiments and analysed data, SPM constructed the pTagRFP::TDP-43^wt and pTagRFP::TDP-43^208–414 plasmids, RZ and BR conceived and directed the study, NV conceived and directed the study, analysed data, prepared figures, wrote the manuscript. All authors read and contributed to the completion of the draft manuscript.

Corresponding author

Correspondence to Nina Vardjan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary material.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Velebit, J., Horvat, A., Smolič, T. et al. Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca²⁺ signaling and dysregulated cell metabolism. Sci Rep 10, 6003 (2020). https://doi.org/10.1038/s41598-020-62864-5

Download citation

Received: 12 September 2019
Accepted: 20 March 2020
Published: 07 April 2020
DOI: https://doi.org/10.1038/s41598-020-62864-5

This article is cited by

Astrocytes in human central nervous system diseases: a frontier for new therapies
- Alexei Verkhratsky
- Arthur Butt
- Michael V. Sofroniew
Signal Transduction and Targeted Therapy (2023)
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity
- Winanto Ng
- Shi-Yan Ng
Translational Neurodegeneration (2022)
Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study
- Kailin Xia
- Linjing Zhang
- Dongsheng Fan
Orphanet Journal of Rare Diseases (2022)
The Role of TDP-43 in Neurodegenerative Disease
- Yan-Zhe Liao
- Jing Ma
- Jie-Zhi Dou
Molecular Neurobiology (2022)
CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?
- Tesfaye Wolde Tefera
- Frederik J. Steyn
- Karin Borges
Cell & Bioscience (2021)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.